Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 in Patients With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2019
At a glance
- Drugs RO 6889450 (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Sponsors Roche
- 10 Dec 2018 Planned End Date changed from 23 Mar 2022 to 2 Jul 2020.
- 10 Dec 2018 Planned primary completion date changed from 23 Mar 2022 to 2 Jul 2020.
- 09 Nov 2018 Status changed from not yet recruiting to recruiting.